Journal ArticleOPEN ACCESS

BCL2 Amplicon Loss and Transcriptional Remodeling Drives ABT-199 Resistance in B Cell Lymphoma Models

Cancer Cell (2019) 35(5) 752-766.e9
DOI: 10.1016/j.ccell.2019.04.005
67Citations
Citations of this article
106Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Zhao et al. show that resistance to the BCL-2 inhibitor ABT-199 is conferred by super enhancer reprogramming and loss of BCL2 amplicons in models of mantle cell lymphoma and double hit lymphoma. Combining ABT-199 with the CDK7 inhibitor THZ1 prevents or reverses BCL-2 inhibitor resistance.

Author supplied keywords

Cite

CITATION STYLE

APA

Zhao, X., Ren, Y., Lawlor, M., Shah, B. D., Park, P. M. C., Lwin, T., … Tao, J. (2019). BCL2 Amplicon Loss and Transcriptional Remodeling Drives ABT-199 Resistance in B Cell Lymphoma Models. Cancer Cell, 35(5), 752-766.e9. https://doi.org/10.1016/j.ccell.2019.04.005

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free